Treatment of low-risk MDS includes immunosuppressant therapy with anti-thymocyte globulin (± cyclosporine) to restore hematopoiesis, as well as erythropoiesis-stimulating agents (ESAs; ± granulocyte colony-stimulating factor) to correct MDS-related anemia [9]. This evidence concerns the gene CSF3 and myelodysplastic syndrome.